Skip to content

Antimicrobial Barrier Dressing Versus Closed-incision Negative Pressure Therapy in the Obese Primary Total Joint Arthroplasty

Antimicrobial Barrier Dressing Versus Closed-incision Negative Pressure Therapy in the Obese Primary Total Joint Arthroplasty

Status
Completed
Phases
Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03345771
Enrollment
230
Registered
2017-11-17
Start date
2017-11-13
Completion date
2021-06-01
Last updated
2022-04-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Osteoarthritis

Brief summary

The purpose of this study is to determine whether an occlusive antimicrobial barrier dressing or portable negative pressure wound dressing is superior in preventing wound complications and infection rates in obese patients undergoing total joint arthroplasty (TJA). Approximately 240 subjects (120 for total knee arthroplasty and 120 for total hip arthroplasty) will be enrolled to evaluate the outcomes associated with silver impregnated dressings and negative pressure wound therapy (NPWT) in treating this subset of patients and analyze the cost benefit of each.

Interventions

COMBINATION_PRODUCTAntimicrobial Barrier Dressing

Ionic Silver is a soft, nonwoven pad or ribbon that features the gelling benefits of Hydrofiber technology plus antimicrobial ionic silver.

PICO provides suction known as negative Pressure wound Therapy (NPWT) which draws out excess fluid from a wound and protects the injured area from getting dirty to ultimately help promote healing. PICO consists of an nPwT pump connected to an absorbent gentle adhesive dressing

Sponsors

NYU Langone Health
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 100 Years
Healthy volunteers
No

Inclusion criteria

* Those identified at pre-operative testing to have an elevated BMI (\> 35)

Exclusion criteria

* Active infection * previous scar or wound healing complication * post traumatic degenerative joint disease (DJD) with hardware * revision surgery * inflammatory arthritis * anticoagulation outside of the standard of care.

Design outcomes

Primary

MeasureTime frameDescription
Visual Analog Scale (VAS) Pain ScoreDay 8A patient is asked to indicate his/her perceived scar severity along a 100 mm horizontal line, and this rating is then measured from the left edge (=VAS score). The total score range is 0 (worst possible scar) to 100 (best possible scar); the higher the score, the better the scarring.
Wound Evaluation Scale (WES)Day 8WES is a 6-item scale. Items 1-5 are scored 0 (yes) or 1 (no), and item 6 is scored 0 (poor) or 1 (acceptable). The total score range is 0-6; the higher the score, the more optimal the wound healing.

Countries

United States

Participant flow

Participants by arm

ArmCount
Antimicrobial Barrier Dressing
postoperative wound dressing with either anti-microbial dressing placed in the operating room from surgery to postoperative day 7 Antimicrobial Barrier Dressing: Ionic Silver is a soft, nonwoven pad or ribbon that features the gelling benefits of Hydrofiber technology plus antimicrobial ionic silver.
115
Closed-incision Negative Pressure Therapy
portable NPWT device placed in the operating room from surgery to postoperative day 7 Negative Pressure Wound Therapy (NPWT): PICO provides suction known as negative Pressure wound Therapy (NPWT) which draws out excess fluid from a wound and protects the injured area from getting dirty to ultimately help promote healing. PICO consists of an nPwT pump connected to an absorbent gentle adhesive dressing
115
Total230

Baseline characteristics

CharacteristicAntimicrobial Barrier DressingTotalClosed-incision Negative Pressure Therapy
Age, Continuous59.87 years
STANDARD_DEVIATION 9.84
60.24 years
STANDARD_DEVIATION 9.56
60.87 years
STANDARD_DEVIATION 9.32
Race (NIH/OMB)
American Indian or Alaska Native
0 Participants0 Participants0 Participants
Race (NIH/OMB)
Asian
0 Participants0 Participants0 Participants
Race (NIH/OMB)
Black or African American
0 Participants0 Participants0 Participants
Race (NIH/OMB)
More than one race
0 Participants0 Participants0 Participants
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
0 Participants0 Participants0 Participants
Race (NIH/OMB)
Unknown or Not Reported
115 Participants230 Participants115 Participants
Race (NIH/OMB)
White
0 Participants0 Participants0 Participants
Region of Enrollment
United States
115 participants230 participants115 participants
Sex: Female, Male
Female
33 Participants66 Participants33 Participants
Sex: Female, Male
Male
82 Participants164 Participants82 Participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
deaths
Total, all-cause mortality
0 / 1150 / 115
other
Total, other adverse events
6 / 1152 / 115
serious
Total, serious adverse events
3 / 1150 / 115

Outcome results

Primary

Visual Analog Scale (VAS) Pain Score

A patient is asked to indicate his/her perceived scar severity along a 100 mm horizontal line, and this rating is then measured from the left edge (=VAS score). The total score range is 0 (worst possible scar) to 100 (best possible scar); the higher the score, the better the scarring.

Time frame: Day 8

ArmMeasureValue (MEAN)Dispersion
Antimicrobial Barrier DressingVisual Analog Scale (VAS) Pain Score64 score on a scaleStandard Deviation 26
Closed-incision Negative Pressure TherapyVisual Analog Scale (VAS) Pain Score61 score on a scaleStandard Deviation 24
Primary

Wound Evaluation Scale (WES)

WES is a 6-item scale. Items 1-5 are scored 0 (yes) or 1 (no), and item 6 is scored 0 (poor) or 1 (acceptable). The total score range is 0-6; the higher the score, the more optimal the wound healing.

Time frame: Day 8

ArmMeasureValue (MEAN)Dispersion
Antimicrobial Barrier DressingWound Evaluation Scale (WES)4.3 score on a scaleStandard Deviation 1.3
Closed-incision Negative Pressure TherapyWound Evaluation Scale (WES)4.2 score on a scaleStandard Deviation 1.7

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026